Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

U.A. Matulonis, R. Shapira-Frommer, A.D. Santin, A.S. Lisyanskaya, S. Pignata, I. Vergote, F. Raspagliesi, G.S. Sonke, M. Birrer, D.M. Provencher, J. Sehouli, N. Colombo, A. González-Martín, A. Oaknin, P.B. Ottevanger, V. Rudaitis, K. Katchar, H. Wu, S. Keefe, J. RumanJ.A. Ledermann

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1080-1087
Number of pages8
JournalAnnals of Oncology
Issue number7
Publication statusPublished - 2019

Cite this